New cancer drug trial aims to stop tumor growth
NCT ID NCT07290088
Summary
This study is testing an experimental immunotherapy called PRL3-Zumab in patients with advanced solid cancers that have spread. The trial aims to see if the treatment can safely slow or stop cancer progression for at least six months. About 52 patients will receive intravenous infusions of the drug every two weeks until their cancer worsens or side effects become too severe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beacon Hospital
RECRUITINGKuala Lumpur, Malaysia
Contact Email: •••••@•••••
-
Hosp. Kuala Lumpur
RECRUITINGKuala Lumpur, Malaysia
Contact Email: •••••@•••••
-
Hosp. Universiti Sains Malaysia (HUSM), Kelantan
RECRUITINGKota Bharu, Malaysia
Contact Email: •••••@•••••
-
University Malaysia Medical Centre
RECRUITINGKuala Lumpur, Malaysia
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.